NCT00032123已完成2 期
A Phase II Study Of OSI-774 (NSC 718781) In Unresectable Or Metastatic Adenocarcinoma Of The Stomach And Gastroesophageal Junction
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 213
研究概览
简要总结
RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor.
PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have locally advanced or metastatic stomach cancer or cancer of the gastroesophageal junction.
详细描述
OBJECTIVES:
- Determine the overall response rate of patients with locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction treated with erlotinib. (Gastric stratum temporarily closed to accrual as of 03/01/2003.)
- Determine the frequency and severity of toxic effects of this drug in these patients.
- Determine the overall survival and time to treatment failure in patients treated with this drug.
- Determine the value of intratumoral expression of epidermal growth factor receptor in predicting patient response to this drug.
OUTLINE: This is a multicenter study. Patients are stratified according to cancer site (stomach vs gastroesophageal junction). (The gastric stratum is temporarily closed to accrual as of 03-01-2003.)
Patients receive oral erlotinib once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients are followed every 6 months for 3 years.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (213)
Loading locations...
相似试验
已完成
2 期
Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerFallopian Tube CancerPeritoneal Cavity CancerOvarian CancerNCT00030446NCIC Clinical Trials Group50
已完成
2 期
Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial CancerEndometrial CancerNCT00030485National Cancer Institute (NCI)
已完成
1 期
Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck CancerHead and Neck CancerNCT00030576University Health Network, Toronto51
已完成
2 期
Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal CancerAdenocarcinoma of the ColonAdenocarcinoma of the RectumRecurrent Colon CancerRecurrent Rectal CancerStage IV Colon CancerStage IV Rectal CancerNCT00032110National Cancer Institute (NCI)30
已完成
2 期
S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar CarcinomaLung CancerNCT00436332SWOG Cancer Research Network84